Illumina (ILMN) said Monday it started a pilot proteomics program to analyze 50,000 UK Biobank samples in partnership with deCODE Genetics, Standard BioTools, Tecan, GSK (GSK), Johnson & Johnson (JNJ), and Novartis (NVS).
Under the collaboration, deCODE Genetics will process the samples from the UK Biobank using Illumina's Protein Prep solution, the company said.
The data generated from the study will be made available to the scientific research community, with the first tranche of the data expected to be released in H2.
Illumina Protein Prep has been in early access limited release and is expected to fully launch in H1.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。